Lobbying

Bright Path Labs's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $80K. Its first report covers Q2 2025; the issues it reports most are Defense and Health Issues.

Bright Path Labs

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$80K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q2 2025
The first quarter a report named it

Lobbying by quarter

Bright Path Labs lobbying by quarter
Bright Path Labs lobbying by quarter
QuarterAmountReports
Q2 2025$20K1
Q3 2025$30K1
Q4 2025$30K1
Q1 2026$30K1
Q2 2026$20K1
Q3 2026$00

By issue

  • Defense$18.3K · 4 reports
  • Health issues$18.3K · 4 reports
  • Manufacturing$18.3K · 4 reports
  • Medical research and clinical labs$18.3K · 4 reports
  • Medicare and Medicaid$18.3K · 4 reports
  • Pharmacy$18.3K · 4 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Centers For Medicare and Medicaid Services (CMS)4 reports
  • Food & Drug Administration (FDA)4 reports
  • Health & Human Services, Dept of (HHS)4 reports
  • HOUSE OF REPRESENTATIVES4 reports
  • SENATE4 reports
  • Voice of America4 reports
  • White House Office4 reports

Firms it paid

Firm
Buchanan Ingersoll & Rooney PC$130K5 quarters

Former officials lobbying for it

Former position
AMANDA LINCOLNStaff Director, Senate Health, Education, Labor, and Pensions Committee; Legislative Director, Sen. Mike Enzi; Health Policy Director, Sen. Susan CollinsQ4 2025

Lobbying reports

Filed by
07/20for Q2Buchanan Ingersoll & Rooney PC$20K
04/20for Q1Buchanan Ingersoll & Rooney PC$30K
01/20for Q4 2025Buchanan Ingersoll & Rooney PC$30K
25/10/20for Q3 2025Buchanan Ingersoll & Rooney PC$30K
25/07/22for Q2 2025Buchanan Ingersoll & Rooney PC$20K
25/06/05for Q2 2025Buchanan Ingersoll & Rooney PCUnder $5,000